TABLE 1.
Mean proportion of HPV-positive women judged not treatable by cryotherapy by midwives and gynecologists, stratified by women’s characteristics
| Mean Proportion Judged Not Treatable* |
||||||
|---|---|---|---|---|---|---|
| Total | Midwives | Gynecologists | ||||
| n | % | Mean | 95% CI | Mean | 95% CI | |
| Total† | 552 | 100 | 30.8 | 28.5–33.3 | 41.2 | 38.5–44.0 |
| Age, y | ||||||
| 25–29 | 166 | 30.1 | 22.6 | 19.7–25.7 | 32.7 | 29.0–36.6 |
| 30–34 | 141 | 25.5 | 27.7 | 25.3–30.1 | 38.2 | 35.4–41.1 |
| 35–39 | 98 | 17.8 | 33.4 | 30.9–36.1 | 44.1 | 41.2–47.0 |
| 40–49 | 108 | 19.6 | 39.7 | 35.8–43.7 | 50.1 | 46.0–54.3 |
| 50–55 | 39 | 7.1 | 46.4 | 40.6–52.2 | 56.2 | 50.3–61.9 |
| P | <0.01 | <0.01 | ||||
| Oral contraceptive use | ||||||
| Never | 117 | 21.2 | 35.6 | 30.2–41.5 | 46.4 | 40.4–52.4 |
| Former user | 268 | 48.6 | 31.6 | 28.3–35.2 | 39.5 | 35.8–43.2 |
| Current user | 167 | 30.3 | 26.2 | 22.4–30.3 | 40.3 | 35.3–45.6 |
| P | 0.01 | 0.19 | ||||
| No. live births | ||||||
| None | 24 | 4.4 | 21.0 | 16.7–26.0 | 29.0 | 23.7–34.9 |
| 1–2 | 183 | 33.2 | 26.3 | 23.3–29.5 | 35.7 | 32.2–39.4 |
| 3–5 | 260 | 47.1 | 32.3 | 29.8–34.9 | 43.1 | 40.2–46.0 |
| 6+ | 85 | 15.4 | 39.0 | 34.2–44.0 | 50.8 | 45.5–56.1 |
| P | <0.01 | <0.01 | ||||
| Women reached menopause | ||||||
| No | 505 | 91.5 | 28.8 | 26.4–31.2 | 39.3 | 36.5–42.1 |
| Yes | 47 | 8.5 | 53.0 | 44.1–61.6 | 61.2 | 51.7–69.9 |
| P | <0.01 | <0.01 | ||||
| No. sexual partners | ||||||
| 1–2 | 350 | 71.4 | 29.2 | 26.3–32.2 | 39.4 | 36.1–42.8 |
| 3–4 | 102 | 20.8 | 32.8 | 29.2–36.5 | 42.9 | 38.8–47.1 |
| 5+ | 38 | 7.8 | 36.6 | 29.4–44.4 | 46.5 | 38.3–54.9 |
| P | 0.08 | 0.14 | ||||
| Enrollment cytology | ||||||
| Normal or reactive changes |
318 | 57.6 | 27.8 | 24.9–30.9 | 40.1 | 36.6–43.8 |
| ASCUS/ atypia |
92 | 16.7 | 34.0 | 28.0–40.4 | 43.2 | 36.8–49.9 |
| LSIL | 71 | 12.9 | 29.3 | 23.5–35.9 | 39.0 | 32.2–46.2 |
| HSIL+ | 71 | 12.9 | 41.9 | 34.9–49.1 | 45.5 | 37.9–53.3 |
| P | <0.01 | 0.35 | ||||
| Disease status at exit‡ | ||||||
| Did not require treatment§ |
403 | 73.0 | 27.8 | 25.2–30.5 | 37.4 | 34.4–40.5 |
| Had disease requiring treatment‖ |
149 | 27.0 | 39.1 | 34.3–44.2 | 51.5 | 45.9–57.0 |
| P | <0.01 | <0.01 | ||||
| Extent of ectopy¶ | ||||||
| Normal | 515 | 93.3 | 30.7 | 28.2–33.2 | 38.5 | 35.8–41.2 |
| Large | 37 | 6.7 | 33.3 | 25.0–42.7 | 78.7 | 69.3–85.8 |
| P | 0.57 | 28.2–33.2 | <0.01 | |||
| Presence of inflammation on enrollment cytology | ||||||
| No | 352 | 63.7 | 27.8 | 24.2–31.6 | 40.6 | 36.2–45.3 |
| Yes | 200 | 36.2 | 32.6 | 29.6–35.7 | 41.5 | 38.2–44.9 |
| P | 0.05 | 0.76 | ||||
Mean proportion judged not treatable based on univariate logistic regression using generalized estimating equations to account for all reviewers examining the same images.
Statistically significant difference between mean proportions judged not treatable by midwives and gynecologists (P < 0.01).
Based on worst histology or HPV testing in PEG clinical record review.
At study exit, women negative for the same HPV type(s) detected at enrollment.
At study exit, women positive for the same HPV type(s) detected at enrollment and/or women diagnosed with CIN2+.
Determination made by lead reviewers during evaluation of enrollment cervical images.3
CI, Confidence interval; ASCUS, Atypical squamous cells of undetermined significance; LSIL, Low-grade squamous intraepithelial lesion; HSIL, High-grade squamous intraepithelial lesion.